ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
Alex I. Zaika(Stony Brook University), Ute M. Moll(Weatherford College), Eva Chalas(Stony Brook University), Christine Sansome(Stony Brook University), Neda Slade(Augustana University), Michael L. Pearl(Stony Brook University), Susan Erster(Stony Brook University), Troy Joseph(Stony Brook University)
Cited by 317
Related Papers
Fractionation and turnover of stable carbon isotopes in animal tissues: Implications for ?13C analysis of diet
|Oecologia|1983|1.8k
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
|Proceedings of the National Academy of Sciences|2007|598
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
|Proceedings of the National Academy of Sciences|1992|580
p63 and p73: Roles in Development and Tumor Formation
|Molecular Cancer Research|2004|492
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.
|Proceedings of the National Academy of Sciences|1995|433